inhaled corticosteroid

DRUG11 trials

Sponsors

Ahvaz Jundishapur University of Medical Science, Kurume University School of Medicine. Division of Respirology, Neurology and rheumatology, Department of Medicine 1, National Heart, Lung, and Blood Institute (NHLBI), University of Alberta, Organon and Co

Conditions

Acute AsthmaAllergic RhinitisAsthmaBacterial PneumoniaChronic Obstructive Pulmonary DiseaseChronic lower respiratory diseases. AsthmaHIV infection Bronchial AsthamaLung Diseases

Phase 3

Pediatric Asthma Controller Trial (PACT)

CompletedNCT00272506

National Heart, Lung, and Blood Institute (NHLBI)Asthma, Lung Diseases

Start: 2002-08-31End: 2004-09-30Updated: 2016-07-12

Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial

CompletedNCT01868113

Makerere UniversityAcute Asthma, Bacterial Pneumonia, Viral Pneumonia

Start: 2012-12-31End: 2014-01-31Updated: 2015-10-27

Does inhaled corticosteroid predispose asthmatic patients to diabetes?

Active, not recruitingIRCT201605247411N2

Ahvaz Jundishapur University of Medical ScienceChronic lower respiratory diseases. Asthma

Start: 2014-07-02Target: 28Updated: 2018-02-22

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

CompletedNCT03930732

SanofiChronic Obstructive Pulmonary Disease

Start: 2019-04-15End: 2023-05-02Updated: 2024-02-28

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

CompletedNCT04456673

SanofiChronic Obstructive Pulmonary Disease

Start: 2020-07-06End: 2024-05-27Updated: 2025-05-29

Phase 4

Asthma/Steroid Withdrawal Study

TerminatedNCT00395239

University of AlbertaAsthma

Start: 2006-10-31End: 2015-10-31Updated: 2016-05-26

Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)

CompletedNCT00442559

Organon and CoAllergic Rhinitis, Asthma

Start: 2005-01-31End: 2007-10-31Updated: 2024-05-13

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

CompletedNCT03467425

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-04-11End: 2019-10-10Updated: 2020-09-07

The predictive value of the acute effect of beclomethasone-dipropionate on an exercise-challenge test for the outcome of longterm treatment with beclomethasone-dipropionate in childhood asthma.

RecruitingNL-OMON47635

Medisch Spectrum Twenteexercise induced bronchoconstriction

Start: 2016-11-05Target: 25Updated: 2024-02-28

Unknown Phase

Correlation between the CD4 cell counts and the pathogenesis and treatment of bronchial asthma.

Active, not recruitingJPRN-UMIN000023817

Kurume University School of Medicine. Division of Respirology, Neurology and rheumatology, Department of Medicine 1HIV infection Bronchial Asthama

Start: 2016-10-10Target: 40Updated: 2025-07-18

The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.

CompletedNCT03611777

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2018-08-14End: 2020-01-31Updated: 2021-04-08

Related Papers

Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.

2025-07-095 citations

Reduction of Exacerbations According to Type 2 Inflammatory Biomarkers With Dupilumab Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab Efficacy in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation Across Baseline Eosinophil Counts

American Journal of Respiratory and Critical Care Medicine2025-05-01

Type 2 Inflammatory Biomarkers and Lung Function Improvement in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Placebo Therapy

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab Efficacy in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation With and Without Emphysema

American Journal of Respiratory and Critical Care Medicine2025-05-01

Impact of Dupilumab on Type 2 Inflammatory Biomarkers in Patients With Chronic Obstructive Pulmonary Disease (COPD)

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab Improves Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation: A Pooled Analysis from the Phase 3 NOTUS and BOREAS Trials

American Journal of Respiratory and Critical Care Medicine2025-05-01

Win Ratio Analysis of BOREAS and NOTUS: Faster Trials, Clearer Wins for Patients With Chronic Obstructive Pulmonary Disease With Type 2 Inflammation

American Journal of Respiratory and Critical Care Medicine2025-05-01

Impact of Dupilumab Treatment on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab Efficacy in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation by Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Breathlessness and St. George's Respiratory Questionnaire (SGRQ) Activity Scores

American Journal of Respiratory and Critical Care Medicine2025-05-01

Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores

Respiratory Medicine2025-02-281 citations

Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.

2025-01-317 citations

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

New England Journal of Medicine2024-05-20192 citations

S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count

2023-11-011 citations

Late Breaking Abstract - Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils

2023-09-09

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

New England Journal of Medicine2023-05-21399 citations

Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.

2023-03-312 citations

Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice

BMJ Open Respiratory Research2022-09-013 citations

Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial

2021-09-051 citations

INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata

2020-09-07

2 more papers not shown